Stephens & Co. Initiates Coverage On Palvella Therapeutics with Overweight Rating, Announces Price Target of $220

Benzinga Newsdesk www.benzinga.com Neutral 65.2%

Neg 0% Neu 65.2% Pos 0%

Stephens & Co. analyst Sudan Loganathan initiates coverage on Palvella Therapeutics (NASDAQ:PVLA) with a Overweight rating and announces Price Target of $220.